STOCK TITAN

Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc.’s Chief Financial Officer, Howard Horn, sold 4,683 shares of common stock in an open-market transaction. The shares were sold at $20.97 each. After this sale, he directly holds 80,351 shares, which include previously reported RSU-based shares that vest over time.

Positive

  • None.

Negative

  • None.
Insider Horn Howard
Role Chief Financial Officer
Sold 4,683 shs ($98K)
Type Security Shares Price Value
Sale Common Stock 4,683 $20.97 $98K
Holdings After Transaction: Common Stock — 80,351 shares (Direct)
Footnotes (1)
  1. F1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Shares sold 4,683 shares Open-market sale of common stock
Sale price per share $20.97 per share Open-market sale by CFO
Shares held after transaction 80,351 shares Direct holdings after sale, including RSU-based shares
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
restricted stock units financial
"shares of common stock underlying RSUs granted to the Reporting Person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
beneficial ownership financial
"previously reported shares of common stock underlying RSUs granted to the Reporting Person"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Ultragenyx (RARE) report for its CFO?

Ultragenyx reported that Chief Financial Officer Howard Horn sold 4,683 shares of common stock in an open-market transaction. The sale was reported on a Form 4 insider filing and reflects a routine disposition of a portion of his holdings.

At what price did Ultragenyx (RARE) CFO Howard Horn sell his shares?

Howard Horn sold 4,683 Ultragenyx common shares at $20.97 per share. This price comes directly from the Form 4 filing and represents the per-share value for this specific open-market sale transaction reported on the transaction date.

How many Ultragenyx (RARE) shares does the CFO hold after the reported sale?

After the sale, Howard Horn directly holds 80,351 shares of Ultragenyx common stock. This figure includes previously reported shares underlying restricted stock units that are subject to vesting conditions, as disclosed in the footnote to the Form 4 filing.

What does the Form 4 footnote say about Ultragenyx (RARE) CFO’s RSUs?

The footnote explains that the reported holdings include shares underlying restricted stock units granted to Howard Horn. These RSUs are subject to specified vesting conditions, meaning the underlying shares are delivered over time as those vesting requirements are satisfied.

Was the Ultragenyx (RARE) CFO’s transaction a purchase or a sale?

The transaction reported for Ultragenyx’s Chief Financial Officer was a sale. The Form 4 identifies it with transaction code “S” and describes it as an open-market sale of 4,683 shares of common stock at a stated per-share price.

Does the Ultragenyx (RARE) Form 4 show any option exercises or derivative trades?

No derivative transactions are shown in this Form 4 excerpt. The filing’s derivative transaction summary is empty, and the single reported transaction is a non-derivative open-market sale of common stock, rather than an option exercise or other derivative-related activity.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Horn Howard

(Last)(First)(Middle)
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT

(Street)
NOVATO CALIFORNIA 94949

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026S4,683D$20.9780,351(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
/s/ Karah Parschauer, attorney-in-fact04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)